Lokelma (sodium zirconium cyclosilicate) / AstraZeneca 
Welcome,         Profile    Billing    Logout  
 0 Diseases   3 Trials   3 Trials   39 News 


12345678910»
  • ||||||||||  Veltassa (patiromer) / CSL Behring, Lokelma (sodium zirconium cyclosilicate) / AstraZeneca
    Review, Journal:  EMCREG-International Multidisciplinary Consensus Panel on Management of Hyperkalemia in Chronic Kidney Disease (CKD) and Heart Failure. (Pubmed Central) -  Feb 12, 2025   
    This consensus emphasizes a multidisciplinary approach to managing hyperkalemia, particularly in patients with cardiovascular kidney metabolic syndrome, to avoid fragmentation of care and ensure comprehensive treatment strategies. The primary goal of this manuscript is to describe strategies to maintain cardiovascular benefits of essential medications while effectively managing potassium levels.
  • ||||||||||  Lokelma (sodium zirconium cyclosilicate) / AstraZeneca
    Trial completion, Enrollment change:  SZC Versus SPS for Treatment of Hyperkalemia in Hemodialysis Patients (clinicaltrials.gov) -  Feb 11, 2025   
    P=N/A,  N=120, Completed, 
    The primary goal of this manuscript is to describe strategies to maintain cardiovascular benefits of essential medications while effectively managing potassium levels. Recruiting --> Completed | N=80 --> 120
  • ||||||||||  Veltassa (patiromer) / CSL Behring, Lokelma (sodium zirconium cyclosilicate) / AstraZeneca
    Review, Journal:  Hyperkalemia management: a multidisciplinary expert panel's perspective on the role of new potassium binders. (Pubmed Central) -  Feb 6, 2025   
    The introduction of patiromer and SZC offers significant advantages over traditional therapies, providing effective and better-tolerated options for patients. The review highlights the role of these novel agents in contemporary hyperkalemia management and calls for ongoing research to further refine treatment protocols and improve patient outcomes.
  • ||||||||||  Lokelma (sodium zirconium cyclosilicate) / AstraZeneca
    Review, Journal:  Sodium zirconium cyclosilicate for MRAs optimization in HFrEF: lessons learned from the REALIZE-K trial. (Pubmed Central) -  Jan 30, 2025   
    Moreover, it explores other significant barriers to MRA optimization, including clinician concerns over the risk of hyperkalemia, a consistent and pervasive issue that often leads to treatment inertia. By addressing both physiological and psychological barriers, this review aims to provide a comprehensive understanding of how to enhance MRA utilization and potentially improve clinical outcomes in patients with HFrEF.
  • ||||||||||  Veltassa (patiromer) / CSL Behring, Lokelma (sodium zirconium cyclosilicate) / AstraZeneca
    Review, Journal:  The role of cation-exchange resins in hyperkalemia management. (Pubmed Central) -  Jan 28, 2025   
    The management of hyperkalemia has evolved, incorporating calcium polystyrene sulfonate (CPS) and newer agents such as sodium zirconium cyclosilicate (SZC) and patiromer alongside traditional treatments. The findings suggest a shift toward
  • ||||||||||  Lokelma (sodium zirconium cyclosilicate) / AstraZeneca
    Trial completion:  CONTINUITY: Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study (clinicaltrials.gov) -  Jan 8, 2025   
    P4,  N=186, Completed, 
    Statistically, neither SZC nor SPS was more efficacious; however, the quicker onset of SZC could provide a clinically meaningful difference in the treatment of acute hyperkalaemia. Active, not recruiting --> Completed
  • ||||||||||  Veltassa (patiromer) / CSL Behring, Lokelma (sodium zirconium cyclosilicate) / AstraZeneca
    Review, Journal:  Utilization of Potassium Binders for the Management of Hyperkalemia in Chronic Kidney Disease: A Position Statement by US Nephrologists. (Pubmed Central) -  Nov 23, 2024   
    Consensus was reached on the following topics: (1) identifying risk factors for hyperkalemia; (2) serum K+ monitoring before and during K+ binder use; (3) utilizing K+ binders in patients receiving renin-angiotensin-aldosterone system inhibitors and dialysis; and (4) when to initiate K+ binders and their duration of use. These consensus statements for the use of K+ binders may assist the nephrology community in optimizing management of hyperkalemia in patients across the spectrum of CKD.
  • ||||||||||  Lokelma (sodium zirconium cyclosilicate) / AstraZeneca
    Enrollment change, Trial completion date, Trial primary completion date:  OPRA-HF: OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure (clinicaltrials.gov) -  Nov 8, 2024   
    P2,  N=110, Recruiting, 
    SZC is a cost-effective alternative for the treatment of HK in patients with CKD or HF, taking into account the reference efficiency values commonly used in Spain. N=230 --> 110 | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026
  • ||||||||||  Columvi (glofitamab-gxbm) / Roche
    Unveiling the Dual Threat: Glofitamab-Induced AKI via Tumor Lysis and Cytokine Release Syndromes () -  Oct 12, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_5371;    
    His tumor was treated with gemcitabine and oxaliplatin to no avail...Due to CRS risk, the patient received obinutuzumab pretreatment...Within 12 hours, he developed symptoms of CRS (fever, tachycardia, and hypotension) and was sent to ICU, received IV fluids, dexamethasone, and tocilizumab, which assisted with stabilizing his vitals...For TLS, he was treated with IV fluids, sodium zirconium cyclosilicate, and sevelamer...As both CRS and TLS can cause AKI, albeit through different mechanisms, nephrologists should closely monitor patients receiving glofitamab for both syndromes.. . .
  • ||||||||||  Lokelma (sodium zirconium cyclosilicate) / AstraZeneca
    Journal:  The Role of Sodium Zirconium Cyclosilicate in Optimizing Heart Failure Therapy. (Pubmed Central) -  Oct 9, 2024   
    Among patients receiving maintenance HD with a history of hyperkalemia, a combination of dK+ 3.0 mEq/L and SZC on non-HD days reduced the rates of AF, CSCA, and post-HD hypokalemia compared with dK+ 2.0 mEq/L and no SZC. No abstract available
  • ||||||||||  Lokelma (sodium zirconium cyclosilicate) / AstraZeneca
    Journal:  Sodium Zirconium Cyclosilicate in HFrEF (Pubmed Central) -  Oct 9, 2024   
    P4
    REALIZE-K is the first trial to evaluate whether SZC can enable rapid and safe MRA optimization and long-term continuation in patients with HFrEF and prevalent/high risk of hyperkalemia. (Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients with Symptomatic HFrEF Receiving Spironolactone [REALIZE-K]; NCT04676646).
  • ||||||||||  Lokelma (sodium zirconium cyclosilicate) / AstraZeneca, Rituxan (rituximab) / Roche
    Potassium of 8? It May Be Okay to Wait (Exhibit Hall, Convention Center) -  Sep 23, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_1411;    
    His renal function improved to a Cr of 1.5 mg/dL and BUN of 18 mg/dL; however, his hyperkalemia persisted, ranging from 5.5 to 6.5 mmol/L, for which he was repeatedly shifted and started on sodium zirconium cyclosilicate TID...Hyperkalemia in CLL is thought to be due to lysis of white cells during the centrifugation step necessary for measuring plasma or serum K. Blood gas analyzers use capillary or venous whole blood samples and do not require centrifugation. Timely recognition of pseudo-hyperkalemia is required to avoid unnecessary and potentially hazardous therapy.
  • ||||||||||  Lokelma (sodium zirconium cyclosilicate) / AstraZeneca
    Updated Design and Status of CONTINUITY: A Phase 4 Study of Continued Postdischarge Sodium Zirconium Cyclosilicate in CKD (Exhibit Hall, Convention Center) -  Sep 23, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_1397;    
    P4
    The CONTINUITY study (estimated completion: Dec 2024) will provide important evidence supporting either SoC or more active sK+ management with a K+ binder post discharge for pts with CKD admitted with HK. Protocol changes allow inclusion of a wider pt population and the potential to improve the clinical relevance of the results.
  • ||||||||||  Lokelma (sodium zirconium cyclosilicate) / AstraZeneca
    Intermittent Sodium Zirconium Cyclosilicate for the Prevention of Hyperkalemia in CKD (Exhibit Hall, Convention Center) -  Sep 23, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_1395;    
    Protocol changes allow inclusion of a wider pt population and the potential to improve the clinical relevance of the results. Intermittent low dose sodium zirconium cyclosilicate is effective for potassium control and enhances the management of hyperkalemia in CKD.
  • ||||||||||  Lokelma (sodium zirconium cyclosilicate) / AstraZeneca
    KAYEXALATE INDUCED MASSIVE BOWEL NECROSIS: TIME TO RETIRE THIS DRUG? (Convention Center Exhibit Hall: Poster Area 2) -  Sep 11, 2024 - Abstract #CHEST2024CHEST_7034;    
    Providers using sodium polystyrene sulfonate should be aware of this life-threatening complication, particularly in patients who have other risk factors. Sodium zirconium cyclosilicate, although expensive, is a safer alternative.
  • ||||||||||  bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases, Lokelma (sodium zirconium cyclosilicate) / AstraZeneca
    COVID-ASSOCIATED ORGANIZING PNEUMONIA WITH CLAD IN A LUNG TRANSPLANT PATIENT (Convention Center Exhibit Hall: Poster Area 2) -  Sep 11, 2024 - Abstract #CHEST2024CHEST_6542;    
    Patients with post COVID pneumonia must be evaluated for organizing pneumonia in order to initiate early treatment. In addition, lung transplant patients who develop COVID infection must be monitored for decline in their lung function.
  • ||||||||||  Lokelma (sodium zirconium cyclosilicate) / AstraZeneca
    Tacrolimus-Induced Type IV Renal Tubular Acidosis in an Orthotopic, Cadaveric Liver Transplant Patient (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_5251;    
    With immediate treatment of intravenous dextrose 5% in water with sodium bicarbonate and sodium zirconium cyclosilicate, renal function, and electrolytes promptly recovered...There may be an increased risk of Type IV RTA in patients on tacrolimus who have a history of CKD or those who have developed CKD after transplantation, as seen in the case we present. As such, hepatologists must be aware of this possibility in tacrolimus treatment for deceased donor liver transplants, as failure to treat, could lead to fatal hyperkalemia, acidosis, increased complications, and mortality.
  • ||||||||||  Lokelma (sodium zirconium cyclosilicate) / AstraZeneca
    Journal:  Reducing the harm associated in treating hyperkalaemia with insulin and dextrose. (Pubmed Central) -  Aug 17, 2024   
    After, establishing a significant burden of hypoglycaemia in the initial observation period, a requirement for hourly-capillary blood glucose monitoring (for up to 6 hours) following the administration of insulin for hyperkalaemia, was incorporated into the guidelines. The two-fold introduction of SZC alongside changes in patient care after the administration of insulin/dextrose, resulted in more appropriate use of insulin/dextrose as well as a significant (73%) reduction in the iatrogenic burden of hypoglycaemia (P=0.04).
  • ||||||||||  Lokelma (sodium zirconium cyclosilicate) / AstraZeneca
    Enrollment change:  SZC Versus SPS for Treatment of Hyperkalemia in Hemodialysis Patients (clinicaltrials.gov) -  Aug 13, 2024   
    P=N/A,  N=80, Recruiting, 
    SZC was effective and safe for the treatment of HK in real-world clinical practice in China. N=60 --> 80
  • ||||||||||  Veltassa (patiromer) / CSL Behring, Lokelma (sodium zirconium cyclosilicate) / AstraZeneca
    Trial completion date, Trial primary completion date:  KBindER: Comparison of Potassium Binders in the ER (clinicaltrials.gov) -  Aug 11, 2024   
    P4,  N=120, Recruiting, 
    N=60 --> 80 Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
  • ||||||||||  Veltassa (patiromer) / CSL Behring, Lokelma (sodium zirconium cyclosilicate) / AstraZeneca
    Journal, HEOR, Cost-analysis:  Cost analysis of patiromer versus sodium zirconium cyclosilicate for the treatment of hyperkalemia in Spain and the UK. (Pubmed Central) -  Aug 5, 2024   
    Extrapolation of patient-level economic outcomes to a population level found that patiromer was associated with annual cost savings of EUR 30.6 million in Spain, and GBP 801.7 million in the UK versus SZC. Patiromer has the potential to be cost saving versus SZC for the treatment of hyperkalemia in Spain and the UK based on the results of a real-world evidence analysis.